Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD)
The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
Alcohol use disorder (AUD) represents a serious public health issue, and discovery of new therapies is a pressing necessity. Alcohol exposure has been widely demonstrated to modulate epigenetic mechanisms, such as histone acetylation/deacetylation balance, in part via histone deacetylase (HDAC) inhibition. Epigenetic factors have been suggested to play a key role in AUD. To date, 18 different mammalian HDAC isoforms have been identified, and these have been divided into four classes. Since recent studies have suggested that both epigenetic mechanisms underlying AUD and the efficacy of HDAC inhibitors (HDACIs) in different animal models of AUD may involve class I HDACs, we herein report the development of class I HDACIs, including information regarding their structure, potency, and selectivity. More effort is required to improve the selectivity, pharmacokinetics, and toxicity profiles of HDACIs to achieve a better understanding of their efficacy in reducing addictive behavior.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For this reason, RGFP966 (Figure 11) has emerged as the most frequently employed tool for HDAC3 pharmacologic inhibition in biological studies [9, 13, 67, 69–71].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [67]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
UniProt: a hub for protein information
The UniProt Consortium (2015) · Nucleic Acids Research · doi:10.1093/nar/gku989 · Cited by 5,106
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Epigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Eberharter, A., & Becker, P. B. (2002) · EMBO reports · doi:10.1093/embo-reports/kvf053 · Cited by 948
(2002) · PubMed · Cited by 732
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle
Deardorff, M. A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., Saitoh, K., Komata, M., Katou, Y., Clark, D., et al. (2012) · Nature · doi:10.1038/nature11316 · Cited by 577
Research works printed but not linked: 6
- 2015, Global Status Report on Alcohol and Health 2014
- Polich, J. M.; Armor, D. J.; Braiker, H. B. Stability and Change in Drinking Patterns in the Course of Alcoholism: Four Years after Treatment . John Wiley & Sons: New York, 1981; pp 159–200.
- 2014, Une Recommandation Temporaire d’Utilisation (RTU) Est Accordée pour le Baclofène—Point d’Information
- Starkman B. G., 2012, Alcohol Res., 34, 293
- Wang C., 2013, Am. J. Nucl. Med. Mol. Imaging, 4, 29
- Furumai R., 2002, Cancer Res., 62, 4916
Cited by
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
Zhao, C., Dong, H., Xu, Q., & Zhang, Y. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1725470 · Cited by 159
“using nonselective HDAC inhibitors should be effective against AUD and the more recent studies have shown that targeting class I HDAC is also effective in different AUD animal models [90].”
MethodDrissi, I., Deschamps, C., Fouquet, G., Alary, R., Peineau, S., Gosset, P., Sueur, H., Marcq, I., Debuysscher, V., Naassïla, M., et al. (2019) · Addiction Biology · doi:10.1111/adb.12760 · Cited by 46
“netic processes that modulate synaptic plasticity may indeed yield to novel treatments for EtOH addiction.(8,17,18) Interestingly, among the 18 isoforms of HDAC, the HDAC2 isoform seems to be particularly implicated in the effects of EtOH as EtOH‐preferring rats knockdown for HDAC2 in the amygdala showed less anxiety‐…”
BackgroundLammers, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.757179 · Cited by 44
Overview of class I HDAC modulators: Inhibitors and degraders
Huang, Z., Zeng, L., Cheng, B., & Li, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116696 · Cited by 36
Metadata
- Authors
- Bourguet, E., Ozdarska, K., Moroy, G., Jeanblanc, J., & Naassila, M.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- INSERM ERi 24, Groupe de Recherche sur l’Alcool et les Pharmacodépendances (GRAP), Université de Picardie Jules Verne, C.U.R.S. (Centre Universitaire de Recherche en Santé), Chemin du Thil, 80000 Amiens, France
- Corresponding author
- Bourguet, Erika
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-08-03
- Volume
- 61
- Issue
- 5
- Pages
- 1745-1766
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2745028397
- Cited by
- 36
- References
- 113
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 3 · 2023: 8 · 2022: 2 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 2
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Minist?re de l'Enseignement Sup?rieur et de la Recherche
- Centre National de la Recherche Scientifique
- Conseil R?gional de Picardie
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- class I HDAC inhibitors, histone deacetylase, alcoholism, epigenetic therapy, histone acetylation, HDAC isoforms, structure-activity relationship, drug selectivity, pharmacokinetics, toxicity, addictive behavior
- MeSH terms
- Alcoholism, Animals, Humans, Therapeutics, Histone Deacetylase Inhibitors, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD). https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b00115
- The paper
- Bourguet, E., Ozdarska, K., Moroy, G., Jeanblanc, J., & Naassila, M. (2018). Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD). Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b00115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.